January 3, 2022 4:34pm

As the oversold revel in and to the upside

Pre-open Indication results: 4 HITs and 2 MISS

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

The Dow closed UP +246.76 points (+0.68%); the S&P closed UP +30.38 points (+0.64%) while the Nasdaq closed UP +187.83 points (+1.20%)



Stock market indexes jumped higher …

Stocks have had a tendency to gain in the start of a new year as investors look to put money to work.

Although volume wasn’t as big as expected on the NYSE and Nasdaq, after a week of quiet trading between Christmas and New Year's Day.


RegMed Investors’ (RMi) pre-open: “a new 2022 beginning, as 2021 is a wrap. After a volatile 2021, the market and cell and gene therapy sector will start the year with anxieties, including the surge in the omicron variant and the likelihood of multiple interest-rates hikes expected later this year.”https://www.regmedinvestors.com/articles/12239


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Monday opened positive at 16 up/13 downs, 5 flat and 1 acquired, stayed positive at the mid-day at 27/5, 2 flats and 1 acquired, ending with a positive close of 32/x0, 2 flats, and 1 acquired;


Pre-open indication results: 4 Hits <Biostage (OTCQB: BSTG -$0.00 with 20 shares traded), Intellia Therapeutics (NTLA +$0.75), Editas Medicine (EDIT +$1.08), Fate Therapeutics (FATE +$1.77)>; 2 MISS <Mesoblast (MESO +$0.18), Sage Therapeutics (SAGE +$1.05)>


Key Metrics:

  • Sector volume was WEAK with 8 of the 32-upside having higher than the 3-month average volume with NADA volume of 0 of 0-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday the IBB closed down -0.16% and XBI closed up +3.09%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -0.65 points or -3.77% at 16.57


Jumping with share pricing momentum (10 of 32):

  • Alnylam Pharmaceuticals (ALNY +$4.33),
  • CRISPR Therapeutics (CRSP +$3.46),
  • Ionis Pharmaceuticals (IONS +$2.17)
  • Vericel (VCEL +$1.77),
  • Fate Therapeutics (FATE +$1.77),
  • Regenxbio (RGNX +$1.61),
  • Global Blood Therapeutics (GBT +$1.19),
  • Editas Medicine (EDIT +$1.08),
  • Sage Therapeutics (SAGE +$1.05),
  • uniQure NV (QURE +$0.76),

Hammered in today’s market (0 of 0):

Closing Flat:

  • 2 – Biostage (OTCQB: BSTG), ReNeuron (RENE.L) and 1- Stemline Therapeutics (STML) – acquired


The BOTTOM LINE: Dreams became reality as the oversold became the nonneglected and blossomed their share pricing.

Reiterating from last year, 2021, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.